Quoin Pharmaceuticals Ltd - ADR
QNRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.04M
Close$
$27.05
571.1% upside
Current Fair Value
571.1% upsideUndervalued by 571.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.04 Million |
|---|---|
| Enterprise Value | $5.19 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-10.63 |
| Beta | 1.66 |
| Outstanding Shares | 2,008,417 |
Return
| Return on Equity | -401958.99% |
|---|---|
| Return on Assets | -132066.01% |
| Return on Invested Capital | -103.94% |
Valuation & Multiples
| P/E Ratio | -0.3 |
|---|---|
| PEG | -0.63 |
| Price to Sales | - |
| Price to Book Ratio | 4.03 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.93 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-1.83
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.61
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 64.70%▲ 4.29% |
|---|---|
| Total Invested | $6.29M▼ 19.57% |
| Investors Holding | 19▼ 1.00% |
ESG Score
No data
About Quoin Pharmaceuticals Ltd
2,020 employeesCellect Biotechnology has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.